Erratum: Oral, capsulized frozen fecal microbiota transplantation for relapsing clostridium difficile infection (JAMA - Journal of the American Medical Association (2014) 312:17 (1772-1778) DOI: 10.1001/jama.2014.13875);Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection

JAMA - Journal of the American Medical Association

Volumn 312, Issue 17, 2014, Pages 1772-1778

  Youngster, Ilan ^a,b   Russell, George H ^a,b   Pindar, Christina ^a   Ziv Baran, Tomer ^c   Sauk, Jenny ^b,d   Hohmann, Elizabeth L ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; FEASIBILITY STUDY; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HEALTH STATUS; HUMAN; INTESTINE MOTILITY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT SAFETY; RECURRENT INFECTION; SCHOOL CHILD; SELF REPORT; VERY ELDERLY; COMPLICATION; CRYOPRESERVATION; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; MICROBIOLOGY; MICROCAPSULE; MICROFLORA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PEPTOCLOSTRIDIUM DIFFICILE; SECONDARY PREVENTION; TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

MICROCAPSULE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAPSULES; CHILD; CLOSTRIDIUM DIFFICILE; CRYOPRESERVATION; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MICROBIOTA; MIDDLE AGED; SECONDARY PREVENTION; TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908681868     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.18379     Document Type: Erratum

References (25)

1. Burke KE, Lamont JT Clostridium difficile infection: a worldwide disease. Gut Liver. 2014; 8(1): 1-6.
2. Khanna S, Baddour LM, Huskins W.C., et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013; 56(10):1401-1406.
3. Rupnik M, Wilcox MH, Gerding DN Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009; 7(7):526-536.
4. Wendt JM, Cohen JA, Mu Y, et al Clostridium difficile infection among children across diverse US geographic locations. Pediatrics. 2014; 133(4):651-658.
5. Louie TJ, Miller MA, Mullane K.M., et al; OPT-80-003 Clinical Study Group. Fidaxomicin vs vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364(5):422-431.
6. Pépin J., Valiquette L, Gagnon S., Routhier S, Brazeau I. Outcomes of Clostridium difficile - associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol. 2007; 102(12):2781-2788.
7. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis P.I., Samonis G., Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012; 40(1):1-8.
8. Petrella LA, Sambol SP, Cheknis A, et al Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C difficile BI strain. Clin Infect Dis. 2012; 55 (3):351-357.
9. Crook DW, Walker AS, Kean Y, et al; Study 003/004 Teams. Fidaxomicin vs vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012; 55(SUPPL. 2):S93-S103.
10. Bartsch SM, Umscheid CA, Fishman N, Lee BY Is fidaxomicin worth the cost? an economic analysis. Clin Infect Dis. 2013; 57(4):555-561.
11. Dutta SK, Girotra M, Garg S., et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2014; 12(9): 1572-1576.
12. Kassam Z, Lee CH, Yuan Y, Hunt RH Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013; 108(4):500-508.
13. van Nood E., Vrieze A, Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368(5):407-415.
14. Austin M, Mellow M, Tierney WM Fecal microbiota transplantation in the treatment of Clostridium difficile infections. Am J Med. 2014; 127 (6):479-483.
15. Youngster I, Sauk J, Pindar C., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014; 58(11): 1515-1522.
16. US Food and Drug Administration. Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies. July 2013. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM361393.pdf. Accessed August 12, 2014.
17. US Food and Drug Administration. Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies: Draft Guidance. March 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM387255.pdf. Accessed August 12, 2014.
18. Bakken JS, Borody T, Brandt L.J., et al; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011; 9 (12):1044-1049.
19. Fridey JL, Townsend MJ, Kessler D.A., Gregory KR. A question of clarity: redesigning the American Association of Blood Banks blood donor history questionnaire - a chronology and model for donor screening. Transfus Med Rev. 2007; 21(3):181-204.
20. Garbacz G, Cadé D, Benameur H, Weitschies W. Biorelevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus. Eur J Pharm Sci. 2014; 57:264-272.
21. Surawicz CM, Brandt LJ, Binion D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4):478-498.
22. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31(5):431-455.
23. Trotti A, Colevas AD, Setser A, et al CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13(3):176-181.
24. Kelly CP, LaMont JT Clostridium difficile - more difficult than ever. N Engl J Med. 2008; 359(18): 1932-1940. doi.
25. Konijeti GG, Sauk J, Shrime M.G., Gupta M., Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis. 2014; 58(11):1507-1514.